A detailed history of Lynch & Associates transactions in Pfizer Inc stock. As of the latest transaction made, Lynch & Associates holds 93,557 shares of PFE stock, worth $2.47 Million. This represents 0.58% of its overall portfolio holdings.

Number of Shares
93,557
Previous 97,182 3.73%
Holding current value
$2.47 Million
Previous $2.72 Million 0.44%
% of portfolio
0.58%
Previous 0.62%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

SELL
$27.7 - $31.39 $100,412 - $113,788
-3,625 Reduced 3.73%
93,557 $2.71 Million
Q2 2024

Aug 06, 2024

BUY
$25.26 - $29.6 $180,634 - $211,669
7,151 Added 7.94%
97,182 $2.72 Million
Q1 2024

Apr 09, 2024

SELL
$25.89 - $29.73 $915,548 - $1.05 Million
-35,363 Reduced 28.2%
90,031 $2.5 Million
Q4 2023

Jan 08, 2024

SELL
$26.13 - $33.94 $799,682 - $1.04 Million
-30,604 Reduced 19.62%
125,394 $3.61 Million
Q3 2023

Oct 24, 2023

SELL
$32.09 - $37.51 $1.21 Million - $1.41 Million
-37,683 Reduced 19.46%
155,998 $5.17 Million
Q2 2023

Oct 24, 2023

SELL
$36.12 - $41.79 $173,520 - $200,759
-4,804 Reduced 2.42%
193,681 $7.1 Million
Q2 2023

Jul 13, 2023

SELL
$36.12 - $41.79 $173,303 - $200,508
-4,798 Reduced 2.42%
193,681 $7.1 Million
Q1 2023

Oct 24, 2023

BUY
$39.39 - $51.28 $189,229 - $246,349
4,804 Added 2.48%
198,485 $8.1 Million
Q1 2023

Apr 04, 2023

SELL
$39.39 - $51.28 $275,296 - $358,395
-6,989 Reduced 3.4%
198,479 $8.1 Million
Q4 2022

Oct 24, 2023

BUY
$41.75 - $54.5 $2.07 Million - $2.7 Million
49,474 Added 31.71%
205,472 $10.5 Million
Q4 2022

Jan 05, 2023

BUY
$41.75 - $54.5 $3,548 - $4,632
85 Added 0.04%
205,468 $10.5 Million
Q3 2022

Oct 03, 2022

SELL
$43.76 - $53.42 $111,281 - $135,847
-2,543 Reduced 1.22%
205,383 $8.99 Million
Q2 2022

Jul 06, 2022

SELL
$46.53 - $55.17 $51,276 - $60,797
-1,102 Reduced 0.53%
207,926 $10.9 Million
Q1 2022

Apr 08, 2022

SELL
$45.75 - $56.69 $298,244 - $369,562
-6,519 Reduced 3.02%
209,028 $10.8 Million
Q4 2021

Jan 11, 2022

BUY
$41.32 - $61.25 $75,409 - $111,781
1,825 Added 0.85%
215,547 $12.7 Million
Q3 2021

Oct 12, 2021

BUY
$39.25 - $50.42 $104,915 - $134,772
2,673 Added 1.27%
213,722 $9.19 Million
Q2 2021

Jul 21, 2021

BUY
$35.91 - $40.68 $80,187 - $90,838
2,233 Added 1.07%
211,049 $8.27 Million
Q1 2021

Apr 09, 2021

BUY
$33.49 - $37.77 $140,959 - $158,973
4,209 Added 2.06%
208,816 $7.57 Million
Q4 2020

Jan 20, 2021

BUY
$33.47 - $42.56 $174,646 - $222,078
5,218 Added 2.62%
204,607 $7.53 Million
Q3 2020

Oct 21, 2020

BUY
$31.75 - $37.25 $18,732 - $21,977
590 Added 0.3%
199,389 $7.32 Million
Q2 2020

Jul 20, 2020

SELL
$30.12 - $36.54 $120,751 - $146,488
-4,009 Reduced 1.98%
198,799 $6.5 Million
Q1 2020

Apr 28, 2020

BUY
$27.03 - $38.62 $82,819 - $118,331
3,064 Added 1.53%
202,808 $6.62 Million
Q4 2019

Jan 10, 2020

SELL
$32.92 - $37.36 $116,043 - $131,694
-3,525 Reduced 1.73%
199,744 $7.83 Million
Q3 2019

Oct 03, 2019

BUY
$32.49 - $42.13 $27,161 - $35,220
836 Added 0.41%
203,269 $7.3 Million
Q2 2019

Jul 19, 2019

BUY
$36.98 - $41.52 $71,334 - $80,092
1,929 Added 0.96%
202,433 $8.77 Million
Q1 2019

Apr 25, 2019

BUY
$37.5 - $41.2 $69,750 - $76,632
1,860 Added 0.94%
200,504 $8.52 Million
Q4 2018

Jan 10, 2019

SELL
$38.47 - $43.86 $884 - $1,008
-23 Reduced 0.01%
198,644 $8.67 Million
Q3 2018

Oct 05, 2018

SELL
$34.47 - $41.81 $142,188 - $172,466
-4,125 Reduced 2.03%
198,667 $8.76 Million
Q2 2018

Jul 09, 2018

BUY
$32.98 - $35.16 $375,345 - $400,155
11,381 Added 5.95%
202,792 $7.36 Million
Q1 2018

Apr 06, 2018

BUY
$31.91 - $37.02 $200,490 - $232,596
6,283 Added 3.39%
191,411 $6.79 Million
Q4 2017

Jan 04, 2018

BUY
$33.26 - $35.29 $103,904 - $110,245
3,124 Added 1.72%
185,128 $6.71 Million
Q3 2017

Oct 18, 2017

BUY
$31.0 - $34.15 $5.64 Million - $6.22 Million
182,004
182,004 $6.5 Million

Others Institutions Holding PFE

About PFIZER INC


  • Ticker PFE
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 5,612,349,952
  • Market Cap $148B
  • Description
  • Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...
More about PFE
Track This Portfolio

Track Lynch & Associates Portfolio

Follow Lynch & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lynch & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Lynch & Associates with notifications on news.